|
Accelovance,Inc.,based in Rockville, Maryland, is a Clinical Research Organization (CRO) that owns Clinical Sites and a Patient Recruitment department with call center. They increase productivity on trials by utilizing high throughput system. Through this integration and patient pooling processes, Accelovance brings an unprecedented level of control to trials. The result is high quality trials completed in compressed timelines and cost effectively.
Each study is approached with the intent to complete enrollment before the study starts. With critical planning and full control of patient recruitment and clinical facility operations, Accelovance is committed to delivering high quality, predictable, and cost effective clinical trials.
Accelovance (China) Corp Ltd.,
Accelovance (China) Corp Ltd.a wholly foreign owned enterprise of Accelovance, Inc., is a clinical CRO and market commercialization services company with offices in Beijing and Shanghai, P.R. China. Accelovance (China) fully leverages its relationship with its parent company, to deliver high quality clinical services in compliance with international standards. In addition, Accelovance (China) works with sponsors to realize the value of the China pharmaceutical market, which is the fastest growing in the world.
Definig & Capitalizing on the Opportunity
China Clinical Services
Understanding the China market opportunities and challenges allows Accelovance to optimize value for sponsors relative to the following needs:
Troubled Study Due to Recruitment
Planned Study in Difficult to Recruit Indications (Oncology, Hepatitis, Infectious Disease, etc.)
Seeking New Markets
Seeking Economic Value
Proof-of-Concept Clinical Studies (Phase I Completed in West)
Fulfill Demographic Requirement
Services
Accelovance (China) operates to deliver ICH-GCP compliant clinical trials. Its staff has strong experience in conducting ICH-GCP clinical trials for multinational client and it utilizes the same clinical SOPs as U.S. based Accelovance, Inc.. Depending on your needs, Accelovance (China) offers the following services:
Regulatory
Project Management
Monitoring
Quality Control/Study Coordination
Data Management/Biostatistics
Market Commercialization
Value
Based on a thorough understanding of your needs, Accelovance is committed to deliver high quality services to help you realize your goals. We look to build long-term relationships and be viewed as a valued partner in your success.
High Quality & Cost Effective Studies
Revenue with Market Entry
Market Registration Services
With a presence in both the United States and China, Accelovance can facilitate the establishment of relationships necessary to optimize a products' revenue potential in the China market. Emphasizing value to its pharmaceutical partners, Accelovance is flexible in the way it structures relationships/partnerships. These structures may include the development of Joint Ventures, Licensing, and/or Broker/Agent. This approach affords partners the opportunity to increase their revenues with as little or as much involvement as they require or have resources to commit.
Accelovance will use its expertise, industry knowledge and its high level government and industry relationships to comprehensively move a product through the following key areas into China’s pharmaceutical marketplace.
-
Market Research
-
Legal (IP, Trademark, etc.)
-
Partner Evaluation/Selection
-
Relationship Structure (JV, Licensing)
-
Develop JV/Partnership Management Structure
-
Business Formation
-
Import Drug Registration
-
Manufacturing/Packaging
-
Marketing & Sales
-
Distribution
Drug development companies can take advantage of the tremendous opportunity in China to increase revenues by entering the world’s fastest growing market. At $7 billion, China is currently the seventh largest pharmaceutical market globally; however, projections from Boston Consulting Group data indicate it will be fifth by 2010 at $24 billion, and some believe in the top three by 2020 at an estimated $120 billion.
|
